{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:40:51Z","timestamp":1791549651185,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clon.2022.06.012","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T05:54:49Z","timestamp":1657950889000},"page":"e85-e93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma"],"prefix":"10.1016","volume":"35","author":[{"given":"L.H.J.","family":"Holtkamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.E.","family":"Nieweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2022.06.012_bib1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jso.25329","article-title":"Re-examining the role of adjuvant radiation therapy","volume":"119","author":"Spillane","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0305-7372(81)80011-4","article-title":"Radiotherapy for malignant melanoma: a re-appraisal","volume":"8","author":"Harwood","year":"1981","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2022.06.012_bib4","first-page":"830","article-title":"The radiation response of human malignant melanoma cells grown in\u00a0vitro","volume":"31","author":"Barranco","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2022.06.012_bib5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1259\/0007-1285-44-526-816","article-title":"The radiosensitivity of melanoma cells in culture","volume":"44","author":"Dewey","year":"1971","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clon.2022.06.012_bib6","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/1097-0142(197612)38:6<2258::AID-CNCR2820380611>3.0.CO;2-H","article-title":"Radiation therapy of malignant melanoma","volume":"38","author":"Habermalz","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.06.012_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0167-8140(86)80048-2","article-title":"Some factors of importance in the radiation treatment of malignant melanoma","volume":"5","author":"Overgaard","year":"1986","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.clon.2022.06.012_bib8","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2008.06.1910","article-title":"Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma","volume":"73","author":"Beadle","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.06.012_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0360-3016(91)90053-7","article-title":"Fraction size in external beam radiation therapy in the treatment of melanoma","volume":"20","author":"Sause","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.06.012_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0360-3016(91)90041-2","article-title":"The optimal radiation dose per fraction for the treatment of malignant melanomas","volume":"20","author":"Trott","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.06.012_bib11","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1200\/JCO.2002.12.094","article-title":"Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial","volume":"20","author":"Hersey","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-003-0429-0","article-title":"Phase I\/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma","volume":"53","author":"Hersey","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clon.2022.06.012_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s00262-004-0587-8","article-title":"Phase I\/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma","volume":"54","author":"Hersey","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clon.2022.06.012_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00262-007-0435-8","article-title":"Phase I\/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma","volume":"57","author":"Hersey","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clon.2022.06.012_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2051-1426-2-9","article-title":"Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma","volume":"2","author":"Coventry","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clon.2022.06.012_bib16","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.radonc.2016.07.013","article-title":"Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications","volume":"120","author":"Popp","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.canlet.2015.03.024","article-title":"Awakening the immune system with radiation: optimal dose and fractionation","volume":"368","author":"Gandhi","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clon.2022.06.012_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2022.06.012_bib20","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1016\/S0167-8140(22)03937-8","article-title":"How may shorter fractionation schedules affect patient care?","volume":"170","author":"Stewart-Lord","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ijrobp.2006.05.056","article-title":"Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation","volume":"66","author":"Chang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.06.012_bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.amjoto.2012.12.014","article-title":"Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence","volume":"34","author":"Mendenhall","year":"2013","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.clon.2022.06.012_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1748-717X-6-12","article-title":"Adjuvant radiation therapy in metastatic lymph nodes from melanoma","volume":"6","author":"Bibault","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","article-title":"Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial","volume":"13","author":"Burmeister","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/(SICI)1097-0347(199710)19:7<589::AID-HED5>3.0.CO;2-3","article-title":"Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma","volume":"19","author":"O\u2019Brien","year":"1997","journal-title":"Head Neck"},{"key":"10.1016\/j.clon.2022.06.012_bib26","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1245\/s10434-008-0087-8","article-title":"Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients?","volume":"15","author":"Moncrieff","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib27","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1002\/cncr.24627","article-title":"The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma","volume":"115","author":"Agrawal","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.06.012_bib28","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1245\/s10434-012-2374-7","article-title":"The management of cervical lymph nodes in patients with cutaneous melanoma","volume":"19","author":"Martin","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clon.2022.06.012_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijrobp.2005.06.030","article-title":"Combined-modality therapy for patients with regional nodal metastases from melanoma","volume":"64","author":"Ballo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.06.012_bib30","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of fast: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522003120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522003120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:52:15Z","timestamp":1760543535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655522003120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0936655522003120"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2022.06.012","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2022.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}